A Phase 2 interventional study of GSK1278863 and Placebo in Anaemia, sponsored by GlaxoSmithKline. Completed at 55 sites in 3 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-11-09.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 16th largest by enrollment, is one of 3 that started in 2012, is one of 10 in phase 2, and was the 3rd registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 18th largest by enrollment, is one of 3 that started in 2012, is one of 11 in phase 2, and was the 8th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in approximately 68 subjects with anemia associated with chronic kidney disease who are not taking rhEPO and are not undergoing dialysis. The range of Hgb values for study eligibility is 8.5-11.0 g/dL. Eligible subjects will be randomized in equal proportions to receive once daily (QD) placebo or GSK1278863 0.5 mg, 2 mg or 5 mg in a double-blind fashion.
This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in approximately 68 subjects with anemia associated with chronic kidney disease who are not taking rhEPO and are not undergoing dialysis. The study consists of a screening phase of up to 2 weeks, a 4-week treatment phase and a 2-week follow-up phase. The range of Hgb values for study eligibility is 8.5-11.0 g/dL. Eligible subjects will be randomized in equal proportions to receive once daily (QD) placebo or GSK1278863 0.5 mg, 2 mg or 5 mg in a double-blind fashion. Study treatment will be stopped if Hgb values fall outside of the range pre-specified in the protocol.
This study aims to estimate the relationship between dose of GSK1278863 and Hgb response for correcting anemia in non-dialysis subjects with CKD who are not taking rhEPO (NDD). In addition, the study will characterize the effect of GSK1278863 on various pharmacokinetic/pharmacodynamic (PK/PD) markers, and will investigate the safety and tolerability of GSK1278863.
An early interim analysis of the Hgb data is planned after approximately 20 subjects from cohort 1 have completed 3 weeks of treatment. Depending upon the interim findings, a second cohort of subjects may be added to investigate an additional GSK1278863 dose arm. Recruitment to the first cohort will continue during the interim analysis.
A second interim analysis is planned after approximately 48 subjects from cohort 1 have completed 4 weeks treatment. The purpose of this interim is three-fold, to investigate whether a second cohort of subjects may be added, to facilitate early development of dose-response and PK/PD statistical models, and to generate interim results to facilitate design and dosing decisions for the next trial.
Subject completion is defined as completion of all study phases including the follow-up phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily
Drug: GSK1278863
Once daily
Drug: GSK1278863
Once daily
Drug: GSK1278863
Once daily
Other: Placebo
Tablet
Tablet
Modeled Hgb Change From Baseline Over 4 Weeks of Treatment
Modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model. The model included fixed effects for baseline Hgb, treatment and a treatment by day interaction. Random effects was fitted in the intercept and the slope over time. All data up until investigational product discontinuation was included for Hgb efficacy evaluable participants; where efficacy evaluable was defined as having a baseline and at least 2 on-treatment Hgb assessments. Baseline was the average of Week -2 , Week -1 and Day 1 visits. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
Time frame: Baseline (average of Week -2, -1 and Day 1) and Week 4
Model-Adjusted Maximum Hgb Changes Over 4 Weeks
Maximum Hgb change over 4 weeks was analyzed using an ANCOVA model with terms included for treatment and baseline Hgb value. Least square mean estimates and 95% CI for each treatment group were reported. Baseline was the average of Week -2 , Week -1 and Day 1 visits. The change from Baseline was calculated by subtracting the baseline value from the individual post-dose visit values.
Time frame: Baseline (average of Week -2 , -1 and Day 1 visits) and 4 weeks
Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb
Number of participants achieving an increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb from baseline were reported. Entry into the study required a target stable Hgb of 8.5-11.0 g/dL. A stable Hgb value was confirmed from three Hgb values taken during the screening period at Week -2, Week -1 and Day 1 (randomization). The average of these three values was used for Baseline Hgb.
Time frame: Up to 4 weeks
Percentage of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb
Percentage of participants achieving an increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb from baseline were reported. Entry into the study requires a target stable Hgb of 8.5-11.0 g/dL. A stable Hgb value was confirmed from three Hgb values taken during the screening period at Week -2, Week -1 and Day 1 (randomization). The average of these three values was used for Baseline Hgb.
Time frame: Up to 4 weeks
Number of Participants Who Reached Hgb Stopping Criteria
The Hgb stopping criteria was defined as reaching to value \<8.0 g/dL, \>=8.0 - \<13.0 (\>= 2g/dL absolute Hgb change over 1 week ) or \>=13.0 g/dL. The number of participants who reached the Hgb stopping criteria of Hgb concentration were presented.
Time frame: Up to Week 4
Change From Baseline in Hepcidin at Week 2 and Week 4
Blood samples for hepcidin were collected at Day 1 (pre-dose), Week 2 (approximately between 4 to 8 h) and Week 4 (pre-dose). Hepcidin is a regulator of iron metabolism. Baseline was the last pre-dose value on Day 1. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values. Where hepcidin values were missing because the value was below the quantification limit (BQL), the BQL value was imputed.
Time frame: Baseline (Pre-dose on Day 1), Week 2 and 4
Change From Baseline in Ferritin at Week 2 and Week 4
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4
Change From Baseline in Transferrin at Week 2 and Week 4
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4
Change From Baseline in Transferrin Saturation at Week 2 and Week 4
Transferrin saturation was measured as a percentage, and is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation was the pre-dose value on Day 1. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4
Change From Baseline in Total Iron Binding Capacity at Week 2 and Week 4
Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4
Change From Baseline in Total Iron at Week 2 and Week 4
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 2 and Week 4
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4
Change From Baseline in Hematocrit and Reticulocytes Over 4 Weeks
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, and 4
Change From Baseline in Erythropoietin at Week 2 and Week 4
Blood samples for erythropoietin were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1 and 3 h after this fist sample) and Week 4 (Pre-dose and 3 h post-dose). The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
Time frame: Baseline (Day 1 Pre-dose), Week 2 and 4
Change From Baseline in Red Blood Cells Count Over 4 Weeks
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
Time frame: Baseline (Day 1 pre-dose), week 1, 2, 3, 4
Change From Baseline in Vascular Endothelial Growth Factor (VEGF) at Week 2 and Week 4
Blood samples for VEGF were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1 and 3 h after this fist sample) and Week 4 (Pre-dose and 3 h post-dose). Baseline was the Day 1 pre-dose value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.
Time frame: Baseline (Pre-dose), week 2 and 4
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.
Time frame: Up to 6 weeks
Number of Participants Discontinuing the Study Treatment Due to AEs
AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. number of participants discontinuing the study treatment due to AEs.
Time frame: Up to 6 weeks
Absolute Values of Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK) at Baseline (Day 1), Week 2, 4, and 6
Clinical chemistry parameters including ALT, ALP, AST, CK were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).
Time frame: Baseline (Day 1 pre-dose), Week 2, 4, and 6
Absolute Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Baseline (Day 1), Week 2, 4, and 6
Clinical chemistry parameters including albumin, apolipoprotein A1, apolipoprotein total, total protein were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).
Time frame: Baseline (Day 1 pre-dose), Week 2, 4, and 6
Absolute Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Baseline (Day 1), Week 2, 4, and 6
Clinical chemistry parameters including calcium, chloride, cholesterol, glucose, inorganic phosphorus, potassium, sodium were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).
Time frame: Baseline (Day 1 pre-dose), Week 2, 4, and 6
Absolute Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Baseline (Day 1), Week 2, 4, and 6
Clinical chemistry parameters including creatinine, direct bilirubin, indirect bilirubin, total bilirubin were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).
Time frame: Baseline (Day 1 pre-dose), Week 2, 4, and 6
Absolute Values of Urine Total Protein/Creatinine Ratio at Baseline (Day 1), Week 2, 4, and 6
Absolute values of urine total protein/creatinine ratio at Baseline (Day 1), Week 2, 4, and follow-up (week 6) were reported.
Time frame: Baseline (Day 1), Week 2, 4, and 6
Change From Baseline Values of ALT, ALP, AST, CK at Week 2, 4, and 6
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the Baseline value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values. Change from Baseline values of ALT, AST, ALP and CK at Week 2, 4, and 6
Time frame: Baseline (Day 1), Week 2, 4, and 6
Change From Baseline Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Week 2, 4, and 6
Baseline values were recorded on Day 1 (Pre dose). If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of albumin, apolipoprotein A1, apolipoprotein total, total protein at Week 2, 4, and 6 were reported.
Time frame: Baseline (Day 1), Week 2, 4, and 6
Change From Baseline Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Week 2, 4, and 6
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of calcium, chloride, cholesterol, glucose, inorganic phosphorus, potassium, sodium at Week 2, 4, and 6 were reported.
Time frame: Baseline (Day 1), Week 2, 4, and 6
Change From Baseline Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Week 2, 4, and 6
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of creatinine, direct bilirubin, indirect bilirubin, total bilirubin at Week 2, 4, and 6 were reported.
Time frame: Baseline (Day 1), Week 2, 4, and 6
Change From Baseline Values of Urine Total Protein/Creatinine Ratio at Week 2, 4, and 6
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of urine total protein/creatinine ratio at Week 2, 4, and 6 were reported.
Time frame: Baseline (Day 1), Week 2, 4, and 6
Absolute Values of Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, WBC Count (Absolute) at Baseline, Week 1, 2, 3, 4, and 6
Hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet count, WBC count (absolute) were assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).
Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Absolute Values of Mean Corpuscle Volume at Baseline, Week 1, 2, 3, 4 and 6
Hematology parameter mean corpuscle volume was assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).
Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Absolute Values of Mean Corpuscle Hgb Concentration at Baseline (Day 1), Week 1, 2, 3, 4, and 6
Hematology parameter Mean Corpuscle Hgb Concentration was assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).
Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Absolute Values of Reticulocyte Count at Baseline (Day 1), Week 1, 2, 3, 4, and 6
Hematology parameter reticulocyte were assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).
Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, WBC Count (Absolute) at Week 1, 2, 3, 4, and 6
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet count, WBC count (absolute) at Week 1, 2, 3, 4, and 6 were reported.
Time frame: Baseline (Day 1), Week 1, 2, 3, 4, and 6
Change From Baseline in Mean Corpuscle Volume at Week 1, 2, 3, 4, and 6
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Mean Corpuscle Volume at Week 1, 2, 3, 4, and 6 were reported.
Time frame: Baseline (Day 1), Week 1, 2, 3, 4, and 6
Change From Baseline in Mean Corpuscle Hgb Concentration at Week 1, 2, 3, 4, and 6
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Mean Corpuscle Hgb Concentration at Week 1, 2, 3, 4, and 6 were reported.
Time frame: Baseline (Day 1), Week 1, 2, 3, 4, and 6
Absolute Values of Systolic Blood Pressure and Diastolic Blood Pressure Baseline, Week 1, Week 2, Week 3, Week 4 and Week 6
Absolute values of systolic blood pressure and diastolic blood pressure Baseline (Day 1), Week 1, 2, 3, 4, and 6 as vital parameters were reported. Three measurements of systolic blood pressure and diastolic blood pressure were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff).
Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at Week 1, 2, 3, 4, and 6
Three measurements of SBP and DBP were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff). Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in systolic blood pressure and diastolic blood pressure at Week 1, 2, 3, 4, and 6 were reported.
Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Absolute Values of Heart Rate at Baseline (Day 1), Week 1, 2, 3, 4, and 6
Absolute values of heart rate at Baseline (Day 1), Week 1, 2, 3, 4, and 6 were reported as vital parameter. Three measurements of heart rate were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff).
Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Change From Baseline in Heart Rate at Week 1, 2, 3, 4, and 6
Three measurements of heart rate were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff). Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. change from baseline in heart rate at Week 1, 2, 3, 4, and 6 were reported.
Time frame: Baseline (Day 1 pre-dose), Week 1, 2, 3, 4, and 6
Absolute Electrocardiogram (ECG) Parameter Values at Baseline (Screening), Week 2, 4, and 6
Full 12-lead ECGs were recorded in participants who were rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. Full 12-lead ECGs were recorded on the provided ECG machine that automatically calculates heart rate, PR, QRS, QT and QTc intervals. Absolute ECG parameters including PR interval, QT interval and QRS duration values at Baseline (Screening), Week 2, 4, and 6 were reported.
Time frame: Baseline (Screening), Week 2, 4, and 6
Change From Baseline in ECG Parameters at Week 2, 4 and 6
Full 12-lead ECGs were recorded in participants who were rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. Full 12-lead ECGs were recorded on the provided ECG machine that automatically calculates heart rate, PR, QRS, QT and QTc intervals. Baseline ECG values were defined as measurements taken at screening. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.
Time frame: Baseline (Screening), Week 2, 4, and 6
Mean Maximum Plasma Concentration (Cmax) of GSK1278863 and GSK1278863 Metabolites
Cmax of GSK1278863 and GSK1278863 metabolites (M1, M2, M3, M4, M5 and M6) were reported. For assessment of Pharmacokinetics parameters blood samples were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this first sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).
Time frame: Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this first sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).
Mean Steady State Area Under the Curve (AUC) of GSK1278863 and GSK1278863 Metabolites
Mean Steady state AUC of GSK1278863 and GSK1278863 metabolites (M1, M2, M3, M4, M5 and M6) were reported. For pharmacokinetic parameter assessment blood samples were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this fist sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).
Time frame: Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this first sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose)
The study was conducted at Canada, Germany, and United States between 29 May 2012 and 30 May 2013. A total of 282 participants were screened, 209 were screen failures and 73 eligible participants were randomized. Entry into the study requires a target stable hemoglobin (Hgb) of 8.5-11.0 gram per deciliter (g/dL).
| Milestone | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Started | 18 | 17 | 18 | 19 |
| Completed | 14 | 12 | 16 | 17 |
| Not completed | 4 | 5 | 2 | 2 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 0 |
| Withdrew: Met haemoglobin stopping criteria | 1 | 1 | 1 | 0 |
Modeled Hgb change from baseline over 4 weeks was derived using a random coefficient mixed effects linear regression model. The model included fixed effects for baseline Hgb, treatment and a treatment by day interaction. Random effects was fitted in the intercept and the slope over time. All data up until investigational product discontinuation was included for Hgb efficacy evaluable participants; where efficacy evaluable was defined as having a baseline and at least 2 on-treatment Hgb assessments. Baseline was the average of Week -2 , Week -1 and Day 1 visits. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
| gram per decilitre (g/dL) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Modeled Hgb Change From Baseline Over 4 Weeks of Treatment | -0.148 ± 0.1925 | 0.132 ± 0.2200 | 0.463 ± 0.2173 | 1.010 ± 0.2614 |
Maximum Hgb change over 4 weeks was analyzed using an ANCOVA model with terms included for treatment and baseline Hgb value. Least square mean estimates and 95% CI for each treatment group were reported. Baseline was the average of Week -2 , Week -1 and Day 1 visits. The change from Baseline was calculated by subtracting the baseline value from the individual post-dose visit values.
| g/dL | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Model-Adjusted Maximum Hgb Changes Over 4 Weeks | 0.153 ± 0.1476 | 0.137 ± 0.1609 | 0.474 ± 0.1532 | 1.069 ± 0.1527 |
Number of participants achieving an increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb from baseline were reported. Entry into the study required a target stable Hgb of 8.5-11.0 g/dL. A stable Hgb value was confirmed from three Hgb values taken during the screening period at Week -2, Week -1 and Day 1 (randomization). The average of these three values was used for Baseline Hgb.
| Participants | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Decrease/increase of < 0.5 g/dL | 16 | 12 | 12 | 4 |
| Increase of >=0.5 g/dL | 3 | 4 | 6 | 14 |
| Increase of >=1 g/dL | 1 | 1 | 2 | 9 |
| Increase of >=1.5 g/dL | 0 | 0 | 0 | 5 |
| Increase of >=2 g/dL | 0 | 0 | 0 | 1 |
Percentage of participants achieving an increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb from baseline were reported. Entry into the study requires a target stable Hgb of 8.5-11.0 g/dL. A stable Hgb value was confirmed from three Hgb values taken during the screening period at Week -2, Week -1 and Day 1 (randomization). The average of these three values was used for Baseline Hgb.
| Percentage of participants | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Decrease/increase of < 0.5 g/dL | 84 | 75 | 67 | 22 |
| Increase of >=0.5 g/dL | 16 | 25 | 33 | 78 |
| Increase of >=1 g/dL | 5 | 6 | 11 | 50 |
| Increase of >=1.5 g/dL | 0 | 0 | 0 | 28 |
| Increase of >=2 g/dL | 0 | 0 | 0 | 6 |
The Hgb stopping criteria was defined as reaching to value \<8.0 g/dL, \>=8.0 - \<13.0 (\>= 2g/dL absolute Hgb change over 1 week ) or \>=13.0 g/dL. The number of participants who reached the Hgb stopping criteria of Hgb concentration were presented.
| Participants | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| <8.0 | 0 | 0 | 1 | 0 |
| >=8.0-<13.0 and >=2.0 decrease | 1 | 0 | 0 | 0 |
| >=8.0-<13.0 and >=2.0 increase | 0 | 1 | 1 | 0 |
Blood samples for hepcidin were collected at Day 1 (pre-dose), Week 2 (approximately between 4 to 8 h) and Week 4 (pre-dose). Hepcidin is a regulator of iron metabolism. Baseline was the last pre-dose value on Day 1. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values. Where hepcidin values were missing because the value was below the quantification limit (BQL), the BQL value was imputed.
| Microgram per Litre (mcg/L) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Week 2 | 10.19 ± 88.535 | -23.46 ± 58.809 | -75.24 ± 88.862 | -120.31 ± 113.653 |
| Week 4 | -2.62 ± 96.176 | -22.16 ± 120.138 | -77.34 ± 96.843 | -143.09 ± 119.617 |
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
| mcg/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Week 2 | 2.6 ± 50.49 | -20.0 ± 40.02 | -38.6 ± 70.20 | -58.8 ± 58.20 |
| Week 4 | -24.3 ± 38.61 | -35.8 ± 54.68 | -8.2 ± 268.77 | -101.8 ± 91.07 |
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
| Grams per litre (G/L) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Week 2 | -0.017 ± 0.2551 | -0.100 ± 0.2194 | 0.153 ± 0.4556 | 0.141 ± 0.7335 |
| Week 4 | 0.011 ± 0.2646 | 0.028 ± 0.2743 | 0.294 ± 0.3442 | 0.388 ± 0.3550 |
Transferrin saturation was measured as a percentage, and is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation was the pre-dose value on Day 1. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
| Percentage of transferrin saturation | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Week 2 | 0.7 ± 7.18 | -1.5 ± 4.16 | -3.7 ± 4.59 | -2.1 ± 6.51 |
| Week 4 | 1.5 ± 6.08 | -3.1 ± 4.85 | -2.6 ± 6.18 | -3.4 ± 11.27 |
Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
| Micromol per litre (micromol/L) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Week 2 | 0.6 ± 5.63 | -1.6 ± 5.08 | 2.9 ± 3.30 | 5.9 ± 6.85 |
| Week 4 | -0.5 ± 3.72 | 0.3 ± 6.34 | 5.1 ± 4.12 | 8.3 ± 5.54 |
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
| micromol/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Week 2 | 0.4 ± 3.71 | -1.1 ± 1.70 | -1.3 ± 2.97 | 0.4 ± 4.14 |
| Week 4 | 0.6 ± 2.82 | -1.7 ± 3.31 | -0.4 ± 3.33 | -0.4 ± 6.10 |
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
| miligram per litre (mg/L) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Week 2 | 6.13 ± 32.236 | 2.35 ± 6.973 | -1.00 ± 13.878 | 4.32 ± 12.337 |
| Week 4 | 0.21 ± 2.212 | 0.65 ± 3.383 | -2.09 ± 11.708 | 1.76 ± 9.378 |
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
| Ratio | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Hematocrit, Week 1 | -0.15 ± 1.385 | -0.29 ± 1.976 | -0.35 ± 0.941 | 0.39 ± 1.616 |
| Hematocrit, Week 2 | 0.35 ± 1.854 | 0.11 ± 1.570 | 0.24 ± 1.683 | 1.64 ± 2.103 |
| Hematocrit, Week 3 | -0.24 ± 1.752 | -0.56 ± 1.148 | 0.08 ± 1.406 | 2.11 ± 2.257 |
| Hematocrit, Week 4 | -0.50 ± 1.958 | -0.14 ± 1.204 | 1.16 ± 2.566 | 3.38 ± 2.052 |
| Reticulocyte, Week 1 | 0.05 ± 0.494 | 0.24 ± 0.443 | 0.46 ± 0.725 | 0.95 ± 0.626 |
| Reticulocyte, Week 2 | 0.01 ± 0.474 | 0.32 ± 0.458 | 0.12 ± 0.685 | 0.85 ± 0.633 |
| Reticulocyte, Week 3 | 0.13 ± 0.479 | 0.23 ± 0.308 | 0.15 ± 0.634 | 0.45 ± 0.525 |
| Reticulocyte, Week 4 | -0.07 ± 0.390 | 0.11 ± 0.375 | -0.07 ± 0.660 | 0.49 ± 0.532 |
Blood samples for erythropoietin were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1 and 3 h after this fist sample) and Week 4 (Pre-dose and 3 h post-dose). The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
| Units per litre (U/L) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Week 2, 4-8 Hours Post-Dose | 0.721 ± 6.1773 | 1.022 ± 4.4319 | 3.622 ± 10.0551 | 13.267 ± 17.8580 |
| Week 2, 5-9 Hours, Post Dose | 1.541 ± 6.6890 | 1.027 ± 4.3872 | 4.612 ± 10.9494 | 15.800 ± 18.5065 |
| Week 2, 7-11 Hours, Post Dose | 0.437 ± 5.4935 | 0.538 ± 4.5382 | 6.630 ± 13.4120 | 20.100 ± 18.5656 |
| Week 4, Pre-dose | 6.644 ± 17.6483 | 0.014 ± 3.9986 | 0.814 ± 6.8894 | 2.975 ± 7.5732 |
| Week 4, 3 Hour Post-Dose | 6.346 ± 18.2978 | 1.039 ± 5.1686 | -0.075 ± 7.6779 | 2.102 ± 6.9180 |
Baseline was the Day 1 pre-dose value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values.
| 10^12 cells /L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Week 1 | -0.01 ± 0.137 | -0.03 ± 0.181 | -0.03 ± 0.113 | 0.04 ± 0.162 |
| Week 2 | 0.02 ± 0.181 | 0.03 ± 0.160 | 0.01 ± 0.165 | 0.14 ± 0.225 |
| Week 3 | -0.03 ± 0.193 | -0.02 ± 0.136 | -0.02 ± 0.147 | 0.16 ± 0.223 |
| Week 4 | -0.05 ± 0.181 | 0.01 ± 0.145 | 0.09 ± 0.254 | 0.33 ± 0.209 |
Blood samples for VEGF were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1 and 3 h after this fist sample) and Week 4 (Pre-dose and 3 h post-dose). Baseline was the Day 1 pre-dose value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.
| Nanogram per litre (ng/L) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| WEEK 2, 4-8 HOURS POST-DOSE | -12.09 ± 62.267 | -17.23 ± 56.519 | -19.55 ± 88.167 | 20.38 ± 60.840 |
| WEEK 2, 5-9 HOURS, POST DOSE | -23.04 ± 104.309 | -18.21 ± 33.258 | -11.80 ± 100.745 | 8.38 ± 39.975 |
| WEEK 2, 7-11 HOURS, POST DOSE | -41.40 ± 133.098 | -30.56 ± 58.602 | -17.88 ± 89.793 | 14.40 ± 41.786 |
| WEEK 4, PRE-DOSE | -39.69 ± 114.265 | 65.89 ± 161.068 | -7.47 ± 29.058 | -1.48 ± 30.874 |
| WEEK 4, 3 HOUR POST-DOSE | -43.33 ± 136.048 | 0.77 ± 37.861 | -3.87 ± 36.521 | 5.56 ± 41.400 |
AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.
| Participants | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Any AEs | 9 | 10 | 5 | 6 |
| Any SAEs | 1 | 0 | 2 | 1 |
AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. number of participants discontinuing the study treatment due to AEs.
| Participants | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Number of Participants Discontinuing the Study Treatment Due to AEs | 1 | 1 | 0 | 0 |
Clinical chemistry parameters including ALT, ALP, AST, CK were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).
| International Units per litre (IU/L) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| ALT, Day 1 | 11.8 ± 4.85 | 13.8 ± 5.74 | 18.8 ± 14.40 | 16.2 ± 7.08 |
| ALT, Week 2 | 10.8 ± 3.68 | 12.4 ± 5.28 | 20.1 ± 23.79 | 14.1 ± 6.26 |
| ALT, Week 4 | 11.4 ± 3.61 | 14.6 ± 8.92 | 22.2 ± 31.12 | 13.2 ± 4.25 |
| ALT, Week 6 | 10.1 ± 3.11 | 14.9 ± 8.57 | 16.9 ± 9.55 | 16.5 ± 6.16 |
| ALP, Day 1 | 86.6 ± 28.50 | 95.6 ± 31.47 | 97.7 ± 30.48 | 85.9 ± 31.47 |
| ALP, Week 2 | 84.3 ± 23.73 | 91.5 ± 28.90 | 92.2 ± 24.56 | 87.2 ± 31.54 |
| ALP, Week 4 | 84.1 ± 23.02 | 90.4 ± 30.57 | 92.6 ± 23.51 | 90.1 ± 34.71 |
| ALP, Week 6 | 83.9 ± 21.32 | 89.2 ± 31.38 | 87.1 ± 20.13 | 92.4 ± 37.56 |
| AST, Day 1 | 16.7 ± 4.51 | 19.1 ± 5.00 | 22.9 ± 14.70 | 18.7 ± 6.68 |
| AST, Week 2 | 16.1 ± 3.21 | 17.5 ± 5.42 | 26.1 ± 22.66 | 19.0 ± 7.08 |
| AST, Week 4 | 15.6 ± 2.44 | 18.2 ± 5.37 | 26.7 ± 29.90 | 17.4 ± 6.06 |
| AST, Week 6 | 15.2 ± 2.81 | 20.1 ± 5.69 | 21.4 ± 7.12 | 19.8 ± 6.77 |
| CK, Day 1 | 101.6 ± 73.24 | 132.4 ± 127.75 | 159.4 ± 129.56 | 94.4 ± 55.38 |
| CK, Week 2 | 86.7 ± 51.04 | 130.8 ± 124.04 | 150.2 ± 92.89 | 100.0 ± 78.25 |
| CK, Week 4 | 94.4 ± 53.19 | 114.2 ± 81.35 | 136.4 ± 111.22 | 83.1 ± 78.25 |
| CK, Week 6 | 90.6 ± 60.11 | 132.2 ± 97.34 | 137.4 ± 82.22 | 130.9 ± 269.29 |
Clinical chemistry parameters including albumin, apolipoprotein A1, apolipoprotein total, total protein were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).
| G/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Albumin, Day 1 | 39.8 ± 3.37 | 40.9 ± 4.12 | 39.7 ± 4.38 | 39.8 ± 3.50 |
| Albumin, Week 2 | 40.8 ± 3.91 | 40.3 ± 5.31 | 38.8 ± 4.38 | 40.1 ± 3.54 |
| Albumin, Week 4 | 40.6 ± 3.00 | 41.3 ± 3.68 | 39.1 ± 4.33 | 39.2 ± 4.10 |
| Albumin, Week 6 | 40.0 ± 4.21 | 39.9 ± 5.04 | 40.6 ± 3.22 | 38.9 ± 3.33 |
| Apolipoprotein A1, Day 1 | 1.481 ± 0.2352 | 1.515 ± 0.2546 | 1.461 ± 0.3561 | 1.572 ± 0.4178 |
| Apolipoprotein A1, Week 2 | 1.418 ± 0.1732 | 1.472 ± 0.2901 | 1.469 ± 0.3142 | 1.370 ± 0.3831 |
| Apolipoprotein A1, Week 4 | 1.482 ± 0.1712 | 1.452 ± 0.3034 | 1.436 ± 0.2553 | 1.405 ± 0.4564 |
| Apolipoprotein A1, Week 6 | 1.472 ± 0.1921 | 1.501 ± 0.2482 | 1.468 ± 0.2514 | 1.492 ± 0.4378 |
| Apolipoprotein Total, Day 1 | 0.794 ± 0.2278 | 0.936 ± 0.2645 | 0.788 ± 0.2419 | 0.792 ± 0.2884 |
| Apolipoprotein Total, Week 2 | 0.754 ± 0.2190 | 0.901 ± 0.2529 | 0.733 ± 0.1921 | 0.751 ± 0.3278 |
| Apolipoprotein Total, Week 4 | 0.720 ± 0.1727 | 0.888 ± 0.2535 | 0.724 ± 0.2071 | 0.743 ± 0.2921 |
| Apolipoprotein Total, Week 6 | 0.732 ± 0.1843 | 0.872 ± 0.2062 | 0.757 ± 0.2286 | 0.776 ± 0.3036 |
| Total Protein, Day 1 | 69.4 ± 8.53 | 71.1 ± 6.41 | 68.5 ± 5.50 | 67.7 ± 4.90 |
| Total Protein, Week 2 | 70.8 ± 9.24 | 70.1 ± 7.81 | 66.4 ± 4.26 | 68.3 ± 4.54 |
| Total Protein, Week 4 | 70.7 ± 10.87 | 71.8 ± 6.53 | 66.9 ± 4.24 | 67.6 ± 6.77 |
| Total Protein, Week 6 | 69.8 ± 9.83 | 69.7 ± 8.36 | 68.3 ± 3.26 | 66.9 ± 4.88 |
Clinical chemistry parameters including calcium, chloride, cholesterol, glucose, inorganic phosphorus, potassium, sodium were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).
| Millimol per Litre (MMOL/L) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Calcium, Day 1 | 2.258 ± 0.1026 | 2.296 ± 0.1404 | 2.259 ± 0.1537 | 2.335 ± 0.1351 |
| Calcium, Week 2 | 2.299 ± 0.0915 | 2.298 ± 0.1472 | 2.331 ± 0.1293 | 2.347 ± 0.1510 |
| Calcium, Week 4 | 2.274 ± 0.0872 | 2.302 ± 0.1234 | 2.301 ± 0.0922 | 2.348 ± 0.1610 |
| Calcium, Week 6 | 2.255 ± 0.1049 | 2.331 ± 0.1861 | 2.309 ± 0.1489 | 2.322 ± 0.1360 |
| Chloride, Day 1 | 105.4 ± 3.05 | 103.1 ± 3.83 | 103.9 ± 5.98 | 104.7 ± 5.11 |
| Chloride, Week 2 | 105.6 ± 2.69 | 104.2 ± 4.31 | 103.6 ± 6.31 | 103.1 ± 5.90 |
| Chloride, Week 4 | 106.6 ± 3.91 | 105.0 ± 4.43 | 104.0 ± 5.56 | 106.4 ± 3.97 |
| Chloride, Week 6 | 106.7 ± 3.52 | 105.3 ± 3.99 | 103.8 ± 6.19 | 104.2 ± 3.90 |
| Cholesterol, Day 1 | 4.147 ± 0.9085 | 4.632 ± 1.2160 | 4.088 ± 1.1424 | 4.411 ± 1.4333 |
| Cholesterol, Week 2 | 3.997 ± 0.7547 | 4.623 ± 1.1469 | 3.800 ± 0.8787 | 4.282 ± 1.5566 |
| Cholesterol, Week 4 | 3.893 ± 0.5880 | 4.448 ± 1.0808 | 3.776 ± 0.9276 | 4.091 ± 1.4236 |
| Cholesterol, Week 6 | 3.944 ± 0.6613 | 4.520 ± 1.0775 | 3.928 ± 1.0253 | 4.406 ± 1.4561 |
| Glucose, Day 1 | 6.97 ± 3.082 | 9.11 ± 5.189 | 9.46 ± 4.840 | 7.75 ± 3.077 |
| Glucose, Week 2 | 6.78 ± 3.333 | 8.48 ± 4.322 | 9.64 ± 4.160 | 9.42 ± 6.596 |
| Glucose, Week 4 | 6.49 ± 3.246 | 9.03 ± 4.940 | 8.63 ± 2.653 | 6.71 ± 2.162 |
| Glucose, Week 6 | 8.88 ± 5.534 | 8.34 ± 3.503 | 9.14 ± 4.243 | 7.81 ± 3.506 |
| Phosphorus, inorganic, Day 1 | 1.325 ± 0.2686 | 1.364 ± 0.2545 | 1.403 ± 0.3165 | 1.313 ± 0.2655 |
| Phosphorus, inorganic, Week 2 | 1.309 ± 0.2116 | 1.421 ± 0.2848 | 1.435 ± 0.3297 | 1.285 ± 0.2871 |
| Phosphorus, inorganic, Week 4 | 1.293 ± 0.2235 | 1.388 ± 0.2922 | 1.403 ± 0.2660 | 1.244 ± 0.2674 |
| Phosphorus, inorganic, Week 6 | 1.319 ± 0.2810 | 1.345 ± 0.2527 | 1.366 ± 0.3567 | 1.203 ± 0.2322 |
| Potassium, Day 1 | 4.57 ± 0.452 | 4.65 ± 0.632 | 4.65 ± 0.489 | 4.63 ± 0.498 |
| Potassium, Week 2 | 4.67 ± 0.410 | 4.61 ± 0.703 | 4.71 ± 0.627 | 4.62 ± 0.593 |
| Potassium, Week 4 | 4.54 ± 0.460 | 4.61 ± 0.468 | 4.56 ± 0.671 | 4.42 ± 0.602 |
| Potassium, Week 6 | 4.56 ± 0.510 | 4.58 ± 0.496 | 4.70 ± 0.520 | 4.65 ± 0.624 |
| Sodium, Day 1 | 140.1 ± 2.65 | 137.8 ± 3.00 | 137.5 ± 3.92 | 138.6 ± 3.45 |
| Sodium, Week 2 | 139.8 ± 2.60 | 137.9 ± 2.00 | 138.2 ± 3.88 | 137.5 ± 4.62 |
| Sodium, Week 4 | 140.6 ± 3.13 | 139.2 ± 2.65 | 138.5 ± 3.59 | 140.2 ± 3.53 |
| Sodium, Week 6 | 140.3 ± 2.46 | 139.4 ± 2.13 | 137.9 ± 4.65 | 138.8 ± 2.83 |
Clinical chemistry parameters including creatinine, direct bilirubin, indirect bilirubin, total bilirubin were assessed at Baseline (Day 1 pre-dose), Week 2, 4, and at follow-up visit (Week 6).
| Micromol/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Creatinine, Day 1 | 250.67 ± 110.117 | 237.05 ± 91.762 | 274.34 ± 146.092 | 237.43 ± 128.461 |
| Creatinine, Week 2 | 235.92 ± 86.636 | 245.16 ± 91.810 | 267.07 ± 166.480 | 217.84 ± 112.543 |
| Creatinine, Week 4 | 242.21 ± 106.796 | 250.10 ± 101.583 | 254.86 ± 149.148 | 209.76 ± 109.374 |
| Creatinine, Week 6 | 244.43 ± 94.682 | 238.07 ± 99.771 | 254.86 ± 171.772 | 219.50 ± 111.645 |
| Direct bilirubin, Day 1 | 1.9 ± 1.11 | 2.1 ± 1.50 | 2.1 ± 1.11 | 1.6 ± 1.07 |
| Direct bilirubin, Week 2 | 1.5 ± 1.12 | 1.7 ± 1.50 | 1.8 ± 0.66 | 2.1 ± 1.11 |
| Direct bilirubin, Week 4 | 1.6 ± 0.85 | 1.8 ± 1.54 | 1.9 ± 0.86 | 1.9 ± 1.11 |
| Direct bilirubin, Week 6 | 1.8 ± 1.44 | 1.8 ± 1.61 | 1.8 ± 0.68 | 2.1 ± 0.86 |
| Indirect bilirubin, Day 1 | 4.0 ± 1.41 | 4.4 ± 1.46 | 4.4 ± 1.46 | 4.6 ± 1.34 |
| Indirect bilirubin, Week 2 | 5.1 ± 2.01 | 4.5 ± 1.55 | 4.8 ± 1.74 | 4.6 ± 2.09 |
| Indirect bilirubin, Week 4 | 4.3 ± 1.07 | 4.2 ± 1.30 | 4.8 ± 1.74 | 4.9 ± 1.75 |
| Indirect bilirubin, Week 6 | 4.4 ± 1.67 | 5.0 ± 2.42 | 4.8 ± 1.24 | 3.8 ± 0.97 |
| Total bilirubin, Day 1 | 5.9 ± 1.50 | 6.5 ± 0.87 | 6.5 ± 1.94 | 6.2 ± 1.62 |
| Total bilirubin, Week 2 | 6.6 ± 2.09 | 6.1 ± 1.41 | 6.6 ± 1.97 | 6.7 ± 2.34 |
| Total bilirubin, Week 4 | 5.9 ± 1.23 | 6.0 ± 1.15 | 6.7 ± 1.99 | 6.8 ± 2.35 |
| Total bilirubin, Week 6 | 6.1 ± 1.36 | 6.8 ± 3.19 | 6.5 ± 1.37 | 5.9 ± 1.50 |
Absolute values of urine total protein/creatinine ratio at Baseline (Day 1), Week 2, 4, and follow-up (week 6) were reported.
| mg/MMOL | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Urine Total Protein/Creatinine ratio, Day 1 | 226.00 ± 268.727 | 205.73 ± 366.100 | 342.39 ± 518.396 | 211.58 ± 241.306 |
| Urine Total Protein/Creatinine ratio, Week 2 | 170.41 ± 194.898 | 207.82 ± 281.943 | 194.14 ± 314.152 | 149.08 ± 135.788 |
| Urine Total Protein/Creatinine ratio, Week 4 | 114.71 ± 130.867 | 169.31 ± 262.401 | 196.37 ± 326.453 | 219.47 ± 280.924 |
| Urine Total Protein/Creatinine ratio, Week 6 | 232.80 ± 381.556 | 162.81 ± 275.606 | 175.16 ± 314.341 | 160.01 ± 192.595 |
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the Baseline value. The change from Baseline was calculated by subtracting the Baseline value from the individual post-dose visit values. Change from Baseline values of ALT, AST, ALP and CK at Week 2, 4, and 6
| IU/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| ALT, Week 2 | -1.1 ± 2.89 | -1.2 ± 3.32 | 3.9 ± 21.85 | -1.9 ± 4.16 |
| ALT, Week 4 | 0.1 ± 3.38 | 0.7 ± 6.79 | 6.0 ± 29.33 | -2.8 ± 7.68 |
| ALT, Week 6 | -1.3 ± 3.09 | 0.7 ± 4.19 | 0.4 ± 7.51 | 0.5 ± 9.02 |
| ALP, Week 2 | 0.8 ± 10.25 | -2.8 ± 12.11 | -1.2 ± 12.31 | 2.7 ± 10.52 |
| ALP, Week 4 | 1.1 ± 8.92 | -4.8 ± 10.49 | -0.8 ± 18.42 | 2.6 ± 8.15 |
| ALP, Week 6 | -1.9 ± 11.51 | -6.4 ± 14.19 | -5.7 ± 19.41 | 4.9 ± 13.40 |
| AST, Week 2 | -0.9 ± 2.66 | -1.7 ± 3.51 | 4.7 ± 21.33 | 0.1 ± 3.92 |
| AST, Week 4 | -1.3 ± 3.24 | -0.5 ± 4.37 | 5.1 ± 28.99 | -1.1 ± 4.70 |
| AST, Week 6 | -1.6 ± 3.03 | -0.1 ± 5.92 | -0.3 ± 7.89 | 1.4 ± 4.66 |
| CK, Week 2 | -18.7 ± 34.45 | 7.9 ± 137.74 | 1.2 ± 61.44 | 4.4 ± 53.00 |
| CK, Week 4 | -21.4 ± 57.79 | -8.5 ± 90.90 | -12.6 ± 66.40 | -7.5 ± 39.31 |
| CK, Week 6 | -19.1 ± 37.64 | -9.4 ± 97.00 | -5.1 ± 63.93 | 40.4 ± 240.54 |
Baseline values were recorded on Day 1 (Pre dose). If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of albumin, apolipoprotein A1, apolipoprotein total, total protein at Week 2, 4, and 6 were reported.
| G/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Albumin, Week 2 | 0.7 ± 1.86 | -0.5 ± 1.92 | -0.9 ± 2.12 | -0.4 ± 2.12 |
| Albumin, Week 4 | 0.4 ± 2.03 | -0.2 ± 2.08 | -0.6 ± 0.87 | -0.6 ± 2.71 |
| Albumin, Week 6 | 0.2 ± 2.01 | -1.2 ± 2.08 | 0.1 ± 1.89 | -1.0 ± 2.65 |
| Apolipoprotein A1, Week 2 | -0.045 ± 0.0887 | -0.063 ± 0.1386 | -0.023 ± 0.1754 | -0.197 ± 0.1641 |
| Apolipoprotein A1, Week 4 | -0.011 ± 0.1144 | -0.061 ± 0.1198 | -0.025 ± 0.1932 | -0.163 ± 0.2133 |
| Apolipoprotein A1, Week 6 | -0.009 ± 0.1287 | -0.026 ± 0.1408 | -0.011 ± 0.1618 | -0.076 ± 0.2743 |
| Apolipoprotein total, Week 2 | -0.016 ± 0.0775 | -0.067 ± 0.1254 | -0.051 ± 0.1312 | -0.048 ± 0.1488 |
| Apolipoprotein total, Week 4 | -0.036 ± 0.0954 | -0.051 ± 0.0910 | -0.055 ± 0.1852 | -0.024 ± 0.2123 |
| Apolipoprotein total, Week 6 | -0.007 ± 0.0952 | -0.077 ± 0.1685 | 0.014 ± 0.2147 | 0.009 ± 0.2194 |
| Total protein, Week 2 | 1.1 ± 3.04 | -0.7 ± 3.03 | -1.3 ± 3.64 | -0.2 ± 2.79 |
| Total protein, Week 4 | 0.5 ± 3.18 | -0.1 ± 3.64 | -0.8 ± 2.65 | 0.2 ± 4.50 |
| Total protein, Week 6 | 0.4 ± 2.73 | -1.5 ± 3.20 | -0.3 ± 2.44 | -0.6 ± 2.92 |
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of calcium, chloride, cholesterol, glucose, inorganic phosphorus, potassium, sodium at Week 2, 4, and 6 were reported.
| MMOL/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Calcium, Week 2 | 0.044 ± 0.0686 | 0.017 ± 0.0767 | 0.032 ± 0.0977 | 0.014 ± 0.0717 |
| Calcium, Week 4 | 0.021 ± 0.1088 | 0.008 ± 0.0870 | -0.000 ± 0.0641 | 0.010 ± 0.0719 |
| Calcium, Week 6 | 0.000 ± 0.1073 | 0.019 ± 0.1192 | -0.001 ± 0.0959 | -0.014 ± 0.0514 |
| Chloride, Week 2 | 0.0 ± 3.59 | 0.9 ± 3.34 | -0.5 ± 4.95 | -1.5 ± 3.54 |
| Chloride, Week 4 | 1.4 ± 2.84 | 1.8 ± 3.26 | -0.1 ± 3.43 | 0.9 ± 3.69 |
| Chloride, Week 6 | 1.1 ± 2.95 | 1.9 ± 3.51 | -0.1 ± 3.94 | -1.3 ± 3.37 |
| Cholesterol, Week 1 | 0.050 ± NA | — | — | — |
| Cholesterol, Week 2 | -0.029 ± 0.2948 | -0.150 ± 0.5398 | -0.256 ± 0.3907 | -0.244 ± 0.6290 |
| Cholesterol, Week 4 | -0.136 ± 0.3060 | -0.195 ± 0.4310 | -0.288 ± 0.6412 | -0.285 ± 0.8511 |
| Cholesterol, Week 6 | -0.134 ± 0.4704 | -0.223 ± 0.7452 | -0.040 ± 0.8412 | 0.029 ± 0.7814 |
| Glucose, Week 2 | 0.35 ± 3.025 | -0.59 ± 5.940 | 0.13 ± 4.375 | 1.67 ± 5.073 |
| Glucose, Week 4 | 0.01 ± 2.893 | -0.21 ± 3.809 | -0.88 ± 3.968 | -0.51 ± 1.957 |
| Glucose, Week 6 | 1.89 ± 3.913 | 0.53 ± 3.725 | -0.57 ± 5.339 | 0.59 ± 2.585 |
| Inorganic phosphorus, Week 2 | 0.012 ± 0.1420 | 0.065 ± 0.1536 | 0.032 ± 0.2277 | 0.026 ± 0.2122 |
| Inorganic phosphorus, Week 4 | 0.025 ± 0.1718 | 0.015 ± 0.1784 | 0.000 ± 0.2430 | -0.032 ± 0.1828 |
| Inorganic phosphorus, Week 6 | 0.003 ± 0.3041 | -0.031 ± 0.1345 | -0.009 ± 0.2478 | -0.074 ± 0.1161 |
| Potassium, Week 2 | 0.10 ± 0.420 | 0.01 ± 0.500 | 0.08 ± 0.558 | -0.02 ± 0.437 |
| Potassium, Week 4 | 0.05 ± 0.470 | -0.02 ± 0.559 | -0.04 ± 0.488 | -0.23 ± 0.541 |
| Potassium, Week 6 | 0.05 ± 0.601 | -0.05 ± 0.385 | 0.06 ± 0.346 | 0.01 ± 0.439 |
| Sodium, Week 2 | -0.3 ± 2.42 | 0.1 ± 2.53 | 0.3 ± 2.80 | -0.9 ± 2.86 |
| Sodium, Week 4 | 0.5 ± 3.78 | 1.6 ± 2.84 | 0.6 ± 2.96 | 1.3 ± 3.72 |
| Sodium, Week 6 | -0.2 ± 2.29 | 1.3 ± 2.87 | 0.1 ± 3.04 | -0.1 ± 2.83 |
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of creatinine, direct bilirubin, indirect bilirubin, total bilirubin at Week 2, 4, and 6 were reported.
| Micromol/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Creatinine, Week 2 | -1.41 ± 22.366 | -0.99 ± 29.854 | 10.78 ± 51.170 | -2.60 ± 18.802 |
| Creatinine, Week 4 | 11.79 ± 20.853 | 1.65 ± 18.800 | -1.44 ± 37.000 | -16.96 ± 23.293 |
| Creatinine, Week 6 | 0.71 ± 46.295 | -5.01 ± 41.477 | 7.24 ± 58.581 | -7.23 ± 29.816 |
| Direct bilirubin, Week 2 | -0.5 ± 1.66 | -0.3 ± 1.99 | -0.4 ± 1.06 | 0.4 ± 1.27 |
| Direct bilirubin, Week 4 | -0.6 ± 1.65 | -0.2 ± 1.74 | -0.2 ± 0.97 | 0.2 ± 1.20 |
| Direct bilirubin, Week 6 | -0.4 ± 1.67 | -0.5 ± 1.13 | -0.4 ± 1.31 | 0.5 ± 0.87 |
| Indirect bilirubin, Week 2 | 1.2 ± 2.13 | 0.1 ± 2.40 | 0.5 ± 1.33 | -0.1 ± 2.39 |
| Indirect bilirubin, Week 4 | 0.4 ± 1.60 | -0.2 ± 2.17 | 0.5 ± 1.66 | 0.5 ± 1.66 |
| Indirect bilirubin, Week 6 | 0.4 ± 2.09 | 0.9 ± 2.17 | 0.3 ± 1.61 | -0.7 ± 0.99 |
| Total bilirubin, Week 2 | 0.7 ± 1.72 | -0.3 ± 1.03 | 0.1 ± 1.32 | 0.2 ± 2.33 |
| Total bilirubin, Week 4 | -0.1 ± 1.23 | -0.5 ± 0.88 | 0.2 ± 1.86 | 0.7 ± 1.21 |
| Total bilirubin, Week 6 | 0.0 ± 1.79 | 0.4 ± 2.53 | -0.1 ± 1.86 | -0.2 ± 0.66 |
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline values of urine total protein/creatinine ratio at Week 2, 4, and 6 were reported.
| MG/MMOL | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Urine Total Protein/Creatinine ratio, Week 2 | 3.44 ± 39.792 | -38.83 ± 97.814 | -115.28 ± 265.028 | -77.98 ± 173.654 |
| Urine Total Protein/Creatinine ratio, Week 4 | -20.56 ± 50.953 | 17.43 ± 58.837 | -99.40 ± 209.678 | 39.90 ± 86.729 |
| Urine Total Protein/Creatinine ratio, Week 6 | 47.22 ± 185.115 | -26.73 ± 67.464 | -72.19 ± 187.792 | -41.40 ± 191.418 |
Hematology parameters including Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet count, WBC count (absolute) were assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).
| 10^9 cells/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Basophils, Day 1 | 0.023 ± 0.0136 | 0.035 ± 0.0255 | 0.025 ± 0.0207 | 0.025 ± 0.0179 |
| Basophils, Week 1 | 0.023 ± 0.0141 | 0.023 ± 0.0086 | 0.034 ± 0.0212 | 0.030 ± 0.0157 |
| Basophils, Week 2 | 0.026 ± 0.0121 | 0.022 ± 0.0153 | 0.024 ± 0.0146 | 0.029 ± 0.0261 |
| Basophils, Week 3 | 0.027 ± 0.0228 | 0.031 ± 0.0166 | 0.024 ± 0.0132 | 0.026 ± 0.0252 |
| Basophils, Week 4 | 0.027 ± 0.0252 | 0.033 ± 0.0303 | 0.023 ± 0.0124 | 0.024 ± 0.0182 |
| Basophils, Week 6 | 0.024 ± 0.0122 | 0.029 ± 0.0138 | 0.023 ± 0.0134 | 0.024 ± 0.0141 |
| Eosinophils, Day 1 | 0.226 ± 0.2505 | 0.205 ± 0.0859 | 0.165 ± 0.1067 | 0.141 ± 0.0657 |
| Eosinophils, Week 1 | 0.212 ± 0.2288 | 0.189 ± 0.1021 | 0.126 ± 0.1054 | 0.169 ± 0.0893 |
| Eosinophils, Week 2 | 0.204 ± 0.2685 | 0.223 ± 0.1274 | 0.122 ± 0.0811 | 0.112 ± 0.0568 |
| Eosinophils, Week 3 | 0.216 ± 0.2127 | 0.212 ± 0.1259 | 0.105 ± 0.0890 | 0.122 ± 0.0831 |
| Eosinophils, Week 4 | 0.191 ± 0.2070 | 0.190 ± 0.0968 | 0.124 ± 0.0928 | 0.146 ± 0.0788 |
| Eosinophils, Week 6 | 0.202 ± 0.2548 | 0.229 ± 0.1294 | 0.134 ± 0.0982 | 0.150 ± 0.1001 |
| Lymphocytes, Day 1 | 1.844 ± 0.5415 | 1.662 ± 0.4552 | 1.473 ± 0.6332 | 1.602 ± 0.7284 |
| Lymphocytes, Week 1 | 1.842 ± 0.7012 | 1.673 ± 0.5261 | 1.677 ± 0.7965 | 1.676 ± 0.4949 |
| Lymphocytes, Week 2 | 1.629 ± 0.4686 | 1.741 ± 0.5192 | 1.356 ± 0.5137 | 1.533 ± 0.4984 |
| Lymphocytes, Week 3 | 1.813 ± 0.5515 | 1.765 ± 0.5392 | 1.475 ± 0.6234 | 1.461 ± 0.4769 |
| Lymphocytes, Week 4 | 1.795 ± 0.4517 | 1.736 ± 0.6919 | 1.428 ± 0.5980 | 1.330 ± 0.4753 |
| Lymphocytes, Week 6 | 1.739 ± 0.4910 | 1.491 ± 0.5122 | 1.427 ± 0.6358 | 1.466 ± 0.4890 |
| Monocytes, Day 1 | 0.384 ± 0.1602 | 0.345 ± 0.1516 | 0.319 ± 0.1405 | 0.373 ± 0.1056 |
| Monocytes, Week 1 | 0.418 ± 0.1731 | 0.375 ± 0.1110 | 0.371 ± 0.1564 | 0.452 ± 0.1438 |
| Monocytes, Week 2 | 0.400 ± 0.2730 | 0.339 ± 0.1533 | 0.305 ± 0.1543 | 0.383 ± 0.1502 |
| Monocytes, Week 3 | 0.452 ± 0.2295 | 0.388 ± 0.1431 | 0.362 ± 0.2196 | 0.418 ± 0.1424 |
| Monocytes, Week 4 | 0.305 ± 0.1420 | 0.388 ± 0.1440 | 0.365 ± 0.1515 | 0.367 ± 0.1030 |
| Monocytes, Week 6 | 0.369 ± 0.1085 | 0.336 ± 0.1363 | 0.350 ± 0.1832 | 0.430 ± 0.2099 |
| Total Neutrophils, Day 1 | 4.654 ± 2.4954 | 4.808 ± 1.8599 | 4.533 ± 1.4186 | 4.614 ± 1.5539 |
| Total Neutrophils, Week 1 | 5.076 ± 4.0917 | 4.670 ± 1.4631 | 4.203 ± 1.1729 | 5.337 ± 1.8429 |
| Total Neutrophils, Week 2 | 4.305 ± 2.1472 | 4.523 ± 1.9377 | 4.121 ± 1.1545 | 4.746 ± 1.6545 |
| Total Neutrophils, Week 3 | 4.588 ± 1.7936 | 4.789 ± 1.8229 | 4.181 ± 1.1934 | 5.011 ± 2.1326 |
| Total Neutrophils, Week 4 | 3.834 ± 1.4080 | 5.238 ± 1.8348 | 4.315 ± 1.5435 | 4.539 ± 2.1457 |
| Total Neutrophils, Week 6 | 4.163 ± 1.6961 | 4.061 ± 1.0597 | 4.126 ± 1.0044 | 4.891 ± 2.2261 |
| Platelet Count, Day 1 | 199.9 ± 67.77 | 229.9 ± 75.44 | 219.2 ± 55.11 | 223.5 ± 54.94 |
| Platelet Count, Week 1 | 204.8 ± 67.74 | 219.8 ± 63.48 | 225.8 ± 57.90 | 238.8 ± 65.47 |
| Platelet Count, Week 2 | 211.3 ± 71.56 | 230.1 ± 67.64 | 209.7 ± 46.40 | 229.9 ± 70.86 |
| Platelet Count, Week 3 | 211.5 ± 71.24 | 237.3 ± 72.13 | 208.5 ± 42.24 | 224.6 ± 63.49 |
| Platelet Count, Week 4 | 184.6 ± 52.35 | 255.8 ± 91.96 | 215.3 ± 52.46 | 240.5 ± 82.69 |
| Platelet Count, Week 6 | 195.1 ± 58.58 | 207.9 ± 78.54 | 217.9 ± 52.66 | 227.1 ± 68.05 |
| WBC count (absolute), Day 1 | 7.14 ± 2.558 | 7.06 ± 2.311 | 6.51 ± 1.570 | 6.76 ± 1.747 |
| WBC count (absolute), Week 1 | 7.56 ± 4.001 | 6.92 ± 1.885 | 6.42 ± 1.740 | 7.67 ± 2.080 |
| WBC count (absolute), Week 2 | 6.57 ± 2.370 | 6.84 ± 2.400 | 5.93 ± 1.099 | 6.80 ± 1.798 |
| WBC count (absolute), Week 3 | 7.11 ± 1.840 | 7.18 ± 2.231 | 6.14 ± 1.275 | 7.04 ± 1.980 |
| WBC count (absolute), Week 4 | 6.16 ± 1.451 | 7.57 ± 2.346 | 6.26 ± 1.617 | 6.42 ± 2.106 |
| WBC count (absolute), Week 6 | 6.50 ± 2.075 | 6.14 ± 1.454 | 6.06 ± 1.044 | 6.97 ± 2.327 |
Hematology parameter mean corpuscle volume was assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).
| Femtolitre (FL) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Mean Corpuscle Volume, Day 1 | 93.8 ± 7.29 | 92.4 ± 5.90 | 94.8 ± 5.50 | 94.2 ± 5.01 |
| Mean Corpuscle Volume, Week 1 | 93.6 ± 7.03 | 92.7 ± 6.64 | 94.6 ± 5.97 | 95.3 ± 3.56 |
| Mean Corpuscle Volume, Week 2 | 93.9 ± 7.34 | 92.8 ± 6.40 | 95.5 ± 5.93 | 95.4 ± 4.78 |
| Mean Corpuscle Volume, Week 3 | 93.6 ± 7.47 | 93.1 ± 6.61 | 95.6 ± 5.79 | 95.9 ± 4.87 |
| Mean Corpuscle Volume, Week 4 | 93.9 ± 7.16 | 93.4 ± 6.58 | 96.1 ± 5.92 | 95.7 ± 5.35 |
| Mean Corpuscle Volume, Week 6 | 94.1 ± 7.23 | 94.1 ± 4.41 | 95.8 ± 5.98 | 95.1 ± 4.81 |
Hematology parameter Mean Corpuscle Hgb Concentration was assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).
| G/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Mean Corpuscle Hgb, Day 1 | 328.6 ± 8.98 | 330.9 ± 5.85 | 330.2 ± 4.74 | 328.4 ± 7.87 |
| Mean Corpuscle Hgb, Week 1 | 329.3 ± 7.47 | 330.1 ± 7.90 | 330.8 ± 6.69 | 328.0 ± 8.46 |
| Mean Corpuscle Hgb, Week 2 | 327.3 ± 7.72 | 329.9 ± 6.78 | 331.3 ± 7.70 | 326.5 ± 8.61 |
| Mean Corpuscle Hgb, Week 3 | 328.4 ± 5.56 | 329.5 ± 7.53 | 331.2 ± 6.12 | 326.0 ± 8.67 |
| Mean Corpuscle Hgb, Week 4 | 329.6 ± 5.81 | 328.8 ± 7.83 | 329.6 ± 3.95 | 326.1 ± 7.52 |
| Mean Corpuscle Hgb, Week 6 | 326.4 ± 7.36 | 330.7 ± 8.70 | 331.4 ± 5.74 | 328.2 ± 8.17 |
Hematology parameter reticulocyte were assessed at Baseline (Day 1 pre-dose), Week 2, 3, 4, and at follow-up visit (Week 6).
| Ratio | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Reticulocytes, Day 1 | 0.0183 ± 0.00584 | 0.0179 ± 0.00494 | 0.0208 ± 0.00747 | 0.0188 ± 0.00757 |
| Reticulocytes, Week 1 | 0.0185 ± 0.00667 | 0.0198 ± 0.00446 | 0.0256 ± 0.01086 | 0.0284 ± 0.00635 |
| Reticulocytes, Week 2 | 0.0178 ± 0.00558 | 0.0201 ± 0.00432 | 0.0224 ± 0.00993 | 0.0268 ± 0.00592 |
| Reticulocytes, Week 3 | 0.0191 ± 0.00641 | 0.0189 ± 0.00388 | 0.0229 ± 0.00943 | 0.0232 ± 0.00570 |
| Reticulocytes, Week 4 | 0.0174 ± 0.00486 | 0.0187 ± 0.00615 | 0.0203 ± 0.00905 | 0.0236 ± 0.00650 |
| Reticulocytes, Week 6 | 0.0154 ± 0.00490 | 0.0196 ± 0.00681 | 0.0161 ± 0.00889 | 0.0142 ± 0.00700 |
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet count, WBC count (absolute) at Week 1, 2, 3, 4, and 6 were reported.
| 10^9 cells/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Basophils, Week 1 | -0.000 ± 0.0153 | -0.011 ± 0.0228 | 0.008 ± 0.0260 | 0.003 ± 0.0214 |
| Basophils, Week 2 | 0.004 ± 0.0145 | -0.013 ± 0.0300 | -0.001 ± 0.0202 | 0.004 ± 0.0336 |
| Basophils, Week 3 | 0.004 ± 0.0229 | -0.005 ± 0.0273 | -0.001 ± 0.0218 | 0.002 ± 0.0221 |
| Basophils, Week 4 | 0.005 ± 0.0241 | -0.000 ± 0.0310 | -0.003 ± 0.0239 | -0.001 ± 0.0232 |
| Basophils, Week 6 | -0.000 ± 0.0157 | -0.003 ± 0.0276 | -0.003 ± 0.0230 | -0.001 ± 0.0169 |
| Eosinophils, Week 1 | -0.014 ± 0.0724 | -0.014 ± 0.0896 | -0.029 ± 0.0841 | 0.023 ± 0.0774 |
| Eosinophils, Week 2 | -0.033 ± 0.0821 | 0.021 ± 0.0914 | -0.013 ± 0.0919 | -0.031 ± 0.0636 |
| Eosinophils, Week 3 | -0.014 ± 0.0908 | 0.012 ± 0.0893 | -0.040 ± 0.0553 | -0.018 ± 0.0695 |
| Eosinophils, Week 4 | -0.020 ± 0.0855 | -0.004 ± 0.0971 | -0.028 ± 0.0881 | 0.011 ± 0.0818 |
| Eosinophils, Week 6 | -0.012 ± 0.0638 | 0.034 ± 0.1241 | -0.018 ± 0.0871 | 0.009 ± 0.1048 |
| Lymphocytes, Week 1 | -0.002 ± 0.4362 | 0.024 ± 0.3340 | 0.126 ± 0.3811 | 0.048 ± 0.3660 |
| Lymphocytes, Week 2 | -0.234 ± 0.2874 | 0.062 ± 0.2353 | -0.176 ± 0.2424 | -0.036 ± 0.3978 |
| Lymphocytes, Week 3 | -0.050 ± 0.2860 | 0.072 ± 0.3048 | -0.028 ± 0.3650 | 0.021 ± 0.3838 |
| Lymphocytes, Week 4 | -0.137 ± 0.3011 | 0.030 ± 0.4575 | -0.082 ± 0.4047 | -0.081 ± 0.3471 |
| Lymphocytes, Week 6 | -0.186 ± 0.3510 | -0.086 ± 0.3537 | -0.083 ± 0.3372 | 0.025 ± 0.3096 |
| Monocytes, Week 1 | 0.034 ± 0.1288 | 0.042 ± 0.1359 | 0.032 ± 0.1258 | 0.096 ± 0.1305 |
| Monocytes, Week 2 | 0.009 ± 0.1702 | 0.029 ± 0.0862 | -0.044 ± 0.1469 | 0.025 ± 0.1182 |
| Monocytes, Week 3 | 0.060 ± 0.1330 | 0.075 ± 0.0859 | 0.015 ± 0.1634 | 0.054 ± 0.1240 |
| Monocytes, Week 4 | -0.039 ± 0.1160 | 0.070 ± 0.0924 | 0.005 ± 0.1120 | -0.007 ± 0.1223 |
| Monocytes, Week 6 | -0.012 ± 0.1245 | 0.006 ± 0.1212 | -0.010 ± 0.1160 | 0.066 ± 0.1579 |
| Total Neutrophils, Week 1 | 0.422 ± 3.6206 | 0.027 ± 0.6517 | -0.362 ± 1.2527 | 0.457 ± 0.9942 |
| Total Neutrophils, Week 2 | 0.155 ± 1.4350 | -0.217 ± 1.0644 | -0.400 ± 0.9470 | 0.086 ± 0.9817 |
| Total Neutrophils, Week 3 | 0.014 ± 1.4591 | -0.101 ± 0.7464 | -0.373 ± 1.0319 | 0.335 ± 1.2442 |
| Total Neutrophils, Week 4 | -0.394 ± 1.7757 | 0.493 ± 0.8534 | -0.239 ± 1.1614 | -0.148 ± 0.9234 |
| Total Neutrophils, Week 6 | -0.229 ± 1.4571 | -0.278 ± 0.6628 | -0.428 ± 1.0110 | 0.215 ± 1.4295 |
| Platelet count, Week 1 | 4.833 ± 21.3906 | -7.375 ± 23.5142 | 6.056 ± 31.6627 | 14.500 ± 19.4672 |
| Platelet count, Week 2 | 16.375 ± 30.2189 | -10.500 ± 26.3373 | 0.200 ± 23.6649 | 12.941 ± 25.5721 |
| Platelet count, Week 3 | 14.118 ± 44.4324 | -3.333 ± 21.8812 | -7.412 ± 26.8632 | 8.176 ± 29.1574 |
| Platelet count, Week 4 | -1.357 ± 12.9591 | 12.417 ± 34.3973 | -0.563 ± 47.3497 | 22.500 ± 46.0232 |
| Platelet count, Week 6 | 8.933 ± 16.1973 | -14.071 ± 44.0742 | 2.063 ± 21.3868 | 10.647 ± 31.0764 |
| WBC count (absolute), Week 1 | 0.422 ± 3.4155 | 0.050 ± 0.7598 | -0.211 ± 1.5885 | 0.639 ± 0.9960 |
| WBC count (absolute), Week 2 | -0.100 ± 1.5786 | -0.136 ± 1.1972 | -0.625 ± 1.0866 | 0.050 ± 1.0377 |
| WBC count (absolute), Week 3 | 0.018 ± 1.5653 | 0.046 ± 0.8373 | -0.435 ± 1.0571 | 0.394 ± 1.3908 |
| WBC count (absolute), Week 4 | -0.579 ± 1.7494 | 0.567 ± 0.8659 | -0.344 ± 1.4846 | -0.206 ± 1.1174 |
| WBC count (absolute), Week 6 | -0.443 ± 1.5994 | -0.336 ± 0.8409 | -0.538 ± 1.0893 | 0.329 ± 1.4347 |
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Mean Corpuscle Volume at Week 1, 2, 3, 4, and 6 were reported.
| FL | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Mean Corpuscle Volume, Week 1 | -0.222 ± 1.3956 | 0.125 ± 1.3601 | -0.222 ± 1.5551 | 0.278 ± 1.1275 |
| Mean Corpuscle Volume, Week 2 | 0.188 ± 1.4705 | -0.214 ± 1.1217 | 0.125 ± 1.4549 | 0.944 ± 0.8726 |
| Mean Corpuscle Volume, Week 3 | -0.235 ± 1.6405 | -0.231 ± 1.0127 | 0.118 ± 1.9327 | 1.176 ± 0.8828 |
| Mean Corpuscle Volume, Week 4 | -0.143 ± 1.9945 | 0.083 ± 1.1645 | 0.188 ± 1.9397 | 1.188 ± 1.5152 |
| Mean Corpuscle Volume, Week 6 | -0.133 ± 1.5523 | -0.071 ± 1.2688 | -0.125 ± 2.2174 | 0.353 ± 1.2719 |
Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in Mean Corpuscle Hgb Concentration at Week 1, 2, 3, 4, and 6 were reported.
| G/L | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Mean Corpuscle Hgb Concentration, Week 1 | 0.667 ± 6.9367 | -0.688 ± 5.3631 | 0.222 ± 5.8767 | -0.389 ± 6.3165 |
| Mean Corpuscle Hgb Concentration, Week 2 | -0.875 ± 8.8835 | -0.214 ± 5.9249 | 0.750 ± 8.2341 | -2.111 ± 5.7792 |
| Mean Corpuscle Hgb Concentration, Week 3 | 0.647 ± 7.7938 | -0.462 ± 6.4371 | 0.294 ± 8.6658 | -2.588 ± 8.5225 |
| Mean Corpuscle Hgb Concentration, Week 4 | 2.429 ± 8.2808 | -1.417 ± 5.0355 | -1.375 ± 6.7318 | -2.625 ± 5.5121 |
| Mean Corpuscle Hgb Concentration, Week 6 | -1.200 ± 7.1534 | -1.714 ± 8.3245 | 0.438 ± 7.8568 | -0.353 ± 8.1620 |
Absolute values of systolic blood pressure and diastolic blood pressure Baseline (Day 1), Week 1, 2, 3, 4, and 6 as vital parameters were reported. Three measurements of systolic blood pressure and diastolic blood pressure were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff).
| Millimeter mercury (mmHg) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Systolic blood pressure, Day 1 | 132.9 ± 14.57 | 135.5 ± 13.50 | 134.0 ± 16.96 | 140.1 ± 15.50 |
| Systolic blood pressure, Week 1 | 132.3 ± 19.26 | 136.0 ± 17.29 | 134.6 ± 20.52 | 137.8 ± 13.29 |
| Systolic blood pressure, Week 2 | 128.4 ± 12.39 | 129.4 ± 19.45 | 129.9 ± 17.18 | 139.1 ± 14.69 |
| Systolic blood pressure, Week 3 | 130.2 ± 13.20 | 133.5 ± 17.28 | 133.0 ± 19.06 | 131.7 ± 12.78 |
| Systolic blood pressure, Week 4 | 132.6 ± 13.94 | 133.1 ± 21.50 | 134.2 ± 14.21 | 135.4 ± 12.97 |
| Systolic blood pressure, Week 6 | 134.3 ± 17.34 | 131.7 ± 19.53 | 135.0 ± 22.79 | 130.4 ± 14.10 |
| Diastolic blood pressure, Day 1 | 69.9 ± 11.70 | 69.0 ± 9.48 | 68.2 ± 8.02 | 71.7 ± 10.03 |
| Diastolic blood pressure, Week 1 | 66.9 ± 11.72 | 68.8 ± 10.72 | 67.4 ± 9.72 | 71.5 ± 10.04 |
| Diastolic blood pressure, Week 2 | 67.7 ± 13.04 | 68.6 ± 10.11 | 66.0 ± 8.71 | 72.7 ± 12.65 |
| Diastolic blood pressure, Week 3 | 67.7 ± 10.41 | 69.5 ± 11.39 | 66.5 ± 10.09 | 66.9 ± 11.35 |
| Diastolic blood pressure, Week 4 | 68.9 ± 12.41 | 68.2 ± 11.94 | 66.2 ± 7.24 | 68.9 ± 10.68 |
| Diastolic blood pressure, Week 6 | 70.3 ± 11.04 | 67.2 ± 8.33 | 66.6 ± 8.26 | 70.1 ± 10.43 |
Three measurements of SBP and DBP were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff). Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. Change from Baseline in systolic blood pressure and diastolic blood pressure at Week 1, 2, 3, 4, and 6 were reported.
| mmHg | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Systolic blood pressure, Week 1 | -0.519 ± 12.4024 | 1.167 ± 7.1874 | 0.565 ± 13.6685 | -2.368 ± 8.9062 |
| Systolic blood pressure, Week 2 | -3.373 ± 9.6414 | -5.786 ± 15.4381 | -5.284 ± 11.6117 | 1.241 ± 15.2259 |
| Systolic blood pressure, Week 3 | -1.529 ± 13.8349 | -1.643 ± 9.4312 | -2.206 ± 13.4641 | -5.216 ± 13.0309 |
| Systolic blood pressure, Week 4 | 0.854 ± 10.1463 | -0.944 ± 13.7693 | 0.844 ± 9.8529 | -1.510 ± 14.4554 |
| Systolic blood pressure, Week 6 | 0.125 ± 15.6446 | -2.458 ± 15.8520 | 1.656 ± 17.5153 | -6.451 ± 15.9295 |
| Diastolic blood pressure, Week 1 | -3.037 ± 8.6409 | 0.521 ± 7.5933 | -0.750 ± 7.5737 | -0.193 ± 6.9711 |
| Diastolic blood pressure, Week 2 | -1.608 ± 12.0348 | -0.024 ± 8.0133 | -2.206 ± 9.0633 | 1.963 ± 7.1189 |
| Diastolic blood pressure, Week 3 | -1.647 ± 8.7998 | 0.857 ± 8.1531 | -1.755 ± 7.8329 | -2.627 ± 7.5414 |
| Diastolic blood pressure, Week 4 | -0.625 ± 5.9590 | -0.111 ± 8.8299 | -1.615 ± 7.8894 | -0.667 ± 7.2024 |
| Diastolic blood pressure, Week 6 | 1.396 ± 7.9807 | -1.312 ± 10.6795 | -1.281 ± 7.7741 | 0.529 ± 8.0830 |
Absolute values of heart rate at Baseline (Day 1), Week 1, 2, 3, 4, and 6 were reported as vital parameter. Three measurements of heart rate were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff).
| Beats per minute | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Heart rate, Day 1 | 68.4 ± 10.78 | 68.4 ± 8.07 | 69.1 ± 14.58 | 67.8 ± 7.53 |
| Heart rate, Week 1 | 68.7 ± 10.33 | 69.5 ± 8.71 | 69.4 ± 12.89 | 69.4 ± 9.80 |
| Heart rate, Week 2 | 68.9 ± 8.95 | 67.5 ± 7.60 | 66.9 ± 13.03 | 67.6 ± 11.46 |
| Heart rate, Week 3 | 71.9 ± 9.92 | 69.8 ± 10.51 | 68.7 ± 14.43 | 66.9 ± 11.96 |
| Heart rate, Week 4 | 67.9 ± 9.50 | 68.5 ± 9.55 | 67.9 ± 16.29 | 65.4 ± 11.97 |
| Heart rate, Week 6 | 71.0 ± 10.63 | 67.6 ± 9.27 | 68.0 ± 10.55 | 68.9 ± 13.01 |
Three measurements of heart rate were recorded from the participant in a supine position for at least 5 minutes (allowed enough time between measurement to completely deflate and loosen the inflatable cuff). Baseline values were recorded on Day 1. If the Day 1 value was missing, the last non-missing value from week -1 or week-2 was represented as the baseline value. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values. change from baseline in heart rate at Week 1, 2, 3, 4, and 6 were reported.
| Beats per minute | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Heart rate, Week 1 | 0.296 ± 7.1005 | 1.375 ± 6.9088 | 0.315 ± 12.5898 | 1.632 ± 7.1258 |
| Heart rate, Week 2 | 0.412 ± 7.6771 | -1.310 ± 7.6051 | -1.333 ± 5.5777 | -0.500 ± 6.8716 |
| Heart rate, Week 3 | 3.392 ± 8.3543 | 0.976 ± 8.3179 | 0.412 ± 6.6558 | -0.510 ± 6.9802 |
| Heart rate, Week 4 | -1.167 ± 8.7271 | 1.111 ± 7.0801 | -0.500 ± 7.0889 | -2.020 ± 7.8391 |
| Heart rate, Week 6 | 1.854 ± 10.9029 | -0.167 ± 7.7993 | -0.458 ± 8.2846 | 0.917 ± 7.5134 |
Full 12-lead ECGs were recorded in participants who were rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. Full 12-lead ECGs were recorded on the provided ECG machine that automatically calculates heart rate, PR, QRS, QT and QTc intervals. Absolute ECG parameters including PR interval, QT interval and QRS duration values at Baseline (Screening), Week 2, 4, and 6 were reported.
| Milliseconds (msec) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| PR Interval, Day 1 | 160.750 ± 31.1849 | 164.727 ± 38.0430 | 165.313 ± 29.3513 | 177.630 ± 23.4002 |
| PR Interval, Week 2 | 165.961 ± 26.2271 | 187.002 ± 38.5301 | 172.909 ± 29.4006 | 176.875 ± 24.4073 |
| PR Interval, Week 4 | 161.689 ± 33.5960 | 180.000 ± 25.7034 | 174.875 ± 29.2025 | 176.000 ± 31.8927 |
| PR Interval, Week 6 | 153.914 ± 19.9718 | 183.314 ± 42.9671 | 175.321 ± 32.9893 | 179.307 ± 31.1222 |
| QRS Duration, Day 1 | 99.750 ± 14.9833 | 101.227 ± 29.7471 | 99.532 ± 9.2023 | 106.444 ± 20.6101 |
| QRS Duration, Week 2 | 107.647 ± 22.2899 | 101.111 ± 19.1603 | 102.328 ± 17.8897 | 106.556 ± 21.4729 |
| QRS Duration, Week 4 | 101.467 ± 20.1127 | 104.205 ± 22.4275 | 103.965 ± 20.4125 | 104.392 ± 25.2312 |
| QRS Duration, Week 6 | 96.186 ± 14.2459 | 104.729 ± 21.0227 | 101.811 ± 18.7734 | 105.617 ± 22.9352 |
| Uncorrected QT Interval, Day 1 | 412.000 ± 33.7554 | 432.455 ± 37.7870 | 405.541 ± 25.1111 | 426.074 ± 25.1141 |
| Uncorrected QT Interval, Week 2 | 411.804 ± 40.7532 | 422.837 ± 35.0150 | 408.936 ± 33.1958 | 419.444 ± 36.1943 |
| Uncorrected QT Interval, Week 4 | 413.111 ± 32.4499 | 413.333 ± 34.7435 | 411.859 ± 42.7345 | 423.255 ± 44.3408 |
| Uncorrected QT Interval, Week 6 | 404.500 ± 34.8993 | 428.077 ± 34.7094 | 396.778 ± 32.4936 | 417.686 ± 45.1037 |
| QTc Interval (Bazett's), Day 1 | 430.833 ± 21.5149 | 446.712 ± 35.2019 | 435.351 ± 30.0154 | 437.593 ± 33.7848 |
| QTc Interval (Bazett's), Week 2 | 440.843 ± 25.7892 | 440.390 ± 24.2664 | 428.144 ± 28.4053 | 431.500 ± 34.3464 |
| QTc Interval (Bazett's), Week 4 | 435.556 ± 23.1025 | 434.590 ± 20.6551 | 429.480 ± 31.0592 | 426.549 ± 32.4467 |
| QTc Interval (Bazett's), Week 6 | 444.771 ± 23.8784 | 441.622 ± 24.7866 | 429.983 ± 30.9609 | 431.700 ± 34.0017 |
| QTc Interval (Fridericias's), Day 1 | 424.417 ± 20.2310 | 441.424 ± 31.0923 | 424.970 ± 23.7320 | 433.815 ± 28.8483 |
| QTc Interval (Fridericias's), Week 2 | 430.549 ± 26.2520 | 434.178 ± 23.6892 | 421.124 ± 22.9709 | 426.944 ± 30.0734 |
| QTc Interval (Fridericias's), Week 4 | 427.711 ± 23.0747 | 427.103 ± 20.4117 | 422.943 ± 28.9082 | 424.961 ± 32.3172 |
| QTc Interval (Fridericias's), Week 6 | 430.357 ± 22.9401 | 436.666 ± 22.8305 | 418.161 ± 24.9461 | 426.591 ± 33.2459 |
Full 12-lead ECGs were recorded in participants who were rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. Full 12-lead ECGs were recorded on the provided ECG machine that automatically calculates heart rate, PR, QRS, QT and QTc intervals. Baseline ECG values were defined as measurements taken at screening. The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.
| msec | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| PR Interval, Week 2 | -1.2 ± 9.22 | 3.6 ± 15.61 | 2.5 ± 9.88 | -0.6 ± 10.80 |
| PR Interval, Week 4 | -2.6 ± 17.37 | 1.8 ± 9.97 | 3.1 ± 12.35 | -2.0 ± 16.16 |
| PR Interval, Week 6 | -5.8 ± 10.70 | 0.5 ± 16.22 | -0.2 ± 16.83 | 1.3 ± 15.67 |
| QRS Duration, Week 2 | 2.5 ± 7.69 | -0.0 ± 5.80 | 0.4 ± 7.29 | 4.6 ± 4.94 |
| QRS Duration, Week 4 | -0.4 ± 13.82 | 1.8 ± 4.80 | 1.3 ± 5.32 | 2.3 ± 8.15 |
| QRS Duration, Week 6 | -0.3 ± 8.07 | 0.2 ± 10.04 | -1.9 ± 6.64 | 3.5 ± 5.07 |
| Uncorrected QT Interval, Week 2 | -10.8 ± 28.14 | -1.9 ± 12.25 | 3.1 ± 15.31 | 5.8 ± 22.23 |
| Uncorrected QT Interval, Week 4 | -2.9 ± 21.31 | -10.9 ± 18.75 | 5.4 ± 17.87 | 8.8 ± 20.89 |
| Uncorrected QT Interval, Week 6 | -7.9 ± 20.94 | -2.4 ± 17.34 | -6.7 ± 15.39 | 3.2 ± 31.45 |
| QTc Interval (Bazett's), Week 2 | 7.9 ± 18.96 | 3.4 ± 11.28 | -4.0 ± 12.98 | 1.7 ± 17.77 |
| QTc Interval (Bazett's), Week 4 | 2.5 ± 15.30 | -0.8 ± 10.26 | -1.8 ± 14.87 | -1.9 ± 19.04 |
| QTc Interval (Bazett's), Week 6 | 11.4 ± 17.49 | 2.9 ± 12.94 | 0.0 ± 20.99 | 3.3 ± 19.38 |
| QTc Interval (Fridericias's), Week 2 | 1.6 ± 12.03 | 1.7 ± 7.80 | -1.7 ± 10.68 | 3.0 ± 17.12 |
| QTc Interval (Fridericias's), Week 4 | 1.0 ± 11.26 | -4.2 ± 10.16 | 0.5 ± 13.54 | 1.6 ± 17.45 |
| QTc Interval (Fridericias's), Week 6 | 4.6 ± 12.04 | 1.0 ± 11.36 | -2.4 ± 15.05 | 3.2 ± 18.08 |
Cmax of GSK1278863 and GSK1278863 metabolites (M1, M2, M3, M4, M5 and M6) were reported. For assessment of Pharmacokinetics parameters blood samples were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this first sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).
| nanogram per millilitre (ng/mL) | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|
| GSK1278863 | 2.68 ± 92.6 | 12.8 ± 121 | 35.7 ± 143 |
| M2 | 1.03 ± 27.9 | 3.83 ± 61.4 | 10.3 ± 61.1 |
| M3 | 1.23 ± 25.1 | 4.45 ± 54.4 | 11.8 ± 64.8 |
| M4 | 0.721 ± 29.7 | 2.74 ± 84.7 | 7.29 ± 116 |
| M5 | 0.296 ± 23.7 | 1.08 ± 49.0 | 2.81 ± 79.8 |
| M6 | 0.455 ± 21.9 | 1.74 ± 56.1 | 4.43 ± 83.1 |
Mean Steady state AUC of GSK1278863 and GSK1278863 metabolites (M1, M2, M3, M4, M5 and M6) were reported. For pharmacokinetic parameter assessment blood samples were collected at Day 1 (pre-dose), Week 2 (first samples was collected approximately between 4 to 8 h and then 1, 2 and 3 h after this fist sample) and Week 4 (Pre-dose 1, 2 and 3 h post-dose).
| ng*hour/mL | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|
| GSK1278863 | 10.3 ± 119 | 51.1 ± 159 | 148 ± 167 |
| M2 | 13.0 ± 38.8 | 51.9 ± 81.3 | 140 ± 65.4 |
| M3 | 17.8 ± 33.4 | 67.1 ± 74.2 | 175 ± 71.6 |
| M4 | 5.54 ± 60.0 | 22.0 ± 99.0 | 63.4 ± 105 |
| M5 | 4.64 ± 27.7 | 17.3 ± 66.7 | 43.5 ± 86.0 |
| M6 | 5.34 ± 36.3 | 21.5 ± 71.4 | 56.3 ± 85.8 |
Collected over Up to follow up contact (Week 6).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/18 (0%) | 1/18 (5.6%) | 8/18 (44.4%) |
| GSK1278863, 0.5 mg | 0/17 (0%) | 0/17 (0%) | 10/17 (58.8%) |
| GSK1278863, 2 mg | 0/18 (0%) | 2/18 (11.1%) | 5/18 (27.8%) |
| GSK1278863, 5 mg | 0/19 (0%) | 1/19 (5.3%) | 5/19 (26.3%) |
| Event | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| Renal failure acuteRenal and urinary disorders | 0/18 | 0/17 | 1/18 | 0/19 |
| Pancreatitis acuteGastrointestinal disorders | 0/18 | 0/17 | 1/18 | 0/19 |
| AppendicitisInfections and infestations | 1/18 | 0/17 | 0/18 | 0/19 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/18 | 0/17 | 1/18 | 0/19 |
| AzotaemiaRenal and urinary disorders | 0/18 | 0/17 | 0/18 | 1/19 |
| Event | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/18 | 2/17 | 0/18 | 1/19 |
| AstheniaGeneral disorders | 1/18 | 1/17 | 0/18 | 0/19 |
| DizzinessNervous system disorders | 1/18 | 1/17 | 0/18 | 0/19 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/18 | 1/17 | 0/18 | 1/19 |
| Urinary tract infectionInfections and infestations | 1/18 | 1/17 | 0/18 | 0/19 |
| VomitingGastrointestinal disorders | 0/18 | 1/17 | 0/18 | 1/19 |
| Abdominal painGastrointestinal disorders | 0/18 | 1/17 | 0/18 | 0/19 |
| Blood creatine phosphokinase increasedInvestigations | 0/18 | 1/17 | 0/18 | 0/19 |
| Conduction disorderCardiac disorders | 0/18 | 1/17 | 0/18 | 0/19 |
| ConstipationGastrointestinal disorders | 0/18 | 1/17 | 0/18 | 0/19 |
| Age, Continuous(Years) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg | Total |
|---|---|---|---|---|---|
| Mean | 69.2 ± 11.00 | 66.6 ± 11.73 | 66.9 ± 11.45 | 71.3 ± 11.26 | 68.6 ± 11.28 |
| Sex: Female, Male(Participants) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg | Total |
|---|---|---|---|---|---|
| Female | 14 | 12 | 10 | 16 | 52 |
| Male | 4 | 5 | 8 | 3 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | GSK1278863, 0.5 mg | GSK1278863, 2 mg | GSK1278863, 5 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 5 | 4 | 5 | 20 |
| Not Hispanic or Latino | 12 | 12 | 14 | 14 | 52 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from May 2012 to primary completion in May 2013, 11 months.
Results were first posted in Nov 2017, 4 years 6 months after primary completion. A results delay was requested in Apr 2015.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 11 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863